Education
About Us
Working with TipRanks
Follow Us
Bioline RX Ltd Sponsored ADR (BLRX)
NASDAQ:BLRX
RESEARCH TOOLSreports
Top Page
Bioline RX Ltd Sponsored ADR
(NASDAQ:BLRX)
48Neutral
Positive Factors
License Agreement
BioLineRx will receive a $10M upfront payment, up to $87M in potential commercial milestones, and royalties on net sales from the license agreement with Ayrmid.
Market Expansion
APHEXDA continues expanding market share, achieving 10% market share of total CXCR4 inhibitor usage in the U.S.
Negative Factors
Debt Repayment
The company repaid $16.5M of ~$29M in total debt, with the remainder due over the next three years at an annual interest rate of ~11%.
Bioline RX Ltd Sponsored ADR (BLRX) vs. S&P 500 (SPY)
Market Cap
$11.58M
Dividend YieldN/A
Average Volume (3M)98.62K
Price to Earnings (P/E)―
Beta (1Y)1.80
Revenue GrowthN/A
EPS Growth68.50%
CountryUS
Employees79
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-10.72
Shares Outstanding3,721,003
10 Day Avg. Volume32,092
30 Day Avg. Volume98,616
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.38
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5.50Price Target Upside80.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Bioline RX Ltd Sponsored ADR Business Overview & Revenue Model
Company DescriptionBioline RX Ltd Sponsored ADR (BLRX) is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of unmet medical needs. The company primarily focuses on oncology, immunology, and other disease areas, leveraging its proprietary platform for drug discovery and development. With a robust pipeline of product candidates, Bioline RX aims to bring innovative solutions to market that can significantly improve patient outcomes.
How the Company Makes MoneyBioline RX Ltd generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company's revenue model includes potential income from product sales, licensing agreements, and strategic partnerships with larger pharmaceutical firms. These collaborations often involve upfront payments, milestone payments, and royalties on sales, contributing to the company's earnings. Bioline RX's financial strategy also relies on securing funding through public and private investments to support ongoing research, clinical trials, and eventual product launches.
Bioline RX Ltd Sponsored ADR Financial Statement Overview
Summary
BLRX demonstrates growth in revenue but continues to face profitability challenges and relies heavily on borrowing, typical for a biotechnology firm in developmental stages. The current financial trajectory suggests a need for careful management of resources to achieve sustainable operations.Income Statement
BLRX showed a significant increase in revenue in the TTM (Trailing-Twelve-Months), growing from a low base. However, the company remains unprofitable with negative EBIT and net income margins, indicating ongoing operational challenges in achieving profitability.45
Neutral
Balance Sheet
The balance sheet reveals a high debt-to-equity ratio, suggesting leveraged operations, yet a reasonable equity ratio indicates some level of asset backing. The company's equity has decreased over recent periods, potentially impacting its financial stability.50
Neutral
Cash Flow
Free cash flow remains negative, reflecting cash burn, typical in biotechnology for research and development. This is offset by positive financing cash flows, indicating reliance on external funding. The operating cash flow to net income ratio shows divergence, highlighting cash flow challenges.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 21.99M | 4.80M | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 15.13M | 1.11M | -654.00K | -702.00K | -934.00K | -940.00K | EBIT |
| -27.84M | -49.69M | -29.16M | -24.78M | -22.93M | -28.11M | EBITDA |
| -12.36M | -57.06M | -28.50M | -25.35M | -21.99M | -27.17M | Net Income Common Stockholders |
| -19.92M | -60.61M | -18.87M | -28.14M | -30.93M | -26.81M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 42.99M | 42.99M | 51.08M | 57.13M | 22.59M | 27.49M | Total Assets |
| 63.92M | 63.92M | 76.38M | 81.39M | 47.29M | 53.57M | Total Debt |
| 11.59M | 11.59M | 12.32M | 4.65M | 7.68M | 10.46M | Net Debt |
| 7.34M | 7.34M | 1.74M | -8.34M | -9.15M | 5.16M | Total Liabilities |
| 50.70M | 50.70M | 25.54M | 13.30M | 25.26M | 20.19M | Stockholders Equity |
| 13.22M | 13.22M | 50.84M | 68.09M | 22.03M | 33.38M |
| Cash Flow | Free Cash Flow | ||||
| -30.35M | -22.91M | -26.56M | -23.67M | -23.21M | -22.74M | Operating Cash Flow |
| -30.27M | -22.61M | -26.24M | -23.57M | -23.21M | -22.67M | Investing Cash Flow |
| -2.18M | 1.44M | 4.01M | -38.22M | 16.67M | 5.26M | Financing Cash Flow |
| 33.51M | 15.06M | 20.44M | 57.75M | 17.87M | 19.19M |
Bioline RX Ltd Sponsored ADR Technical Analysis
Negative
3.05
Price Trends
4.39
Negative
9.16
Negative
17.69
Negative
Market Momentum
-0.39
Negative
33.52
Neutral
46.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLRX, the sentiment is Negative. The current price of 3.05 is below the 20-day moving average (MA) of 3.42, below the 50-day MA of 4.39, and below the 200-day MA of 17.69, indicating a bearish trend. The MACD of -0.39 indicates Negative momentum. The RSI at 33.52 is Neutral, neither overbought nor oversold. The STOCH value of 46.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLRX.
Bioline RX Ltd Sponsored ADR Risk Analysis
Bioline RX Ltd Sponsored ADR disclosed 43 risk factors in its most recent earnings report. Bioline RX Ltd Sponsored ADR reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bioline RX Ltd Sponsored ADR Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $10.41B | 20.76 | 23.13% | ― | 18.49% | 176.71% | |
52 Neutral | $5.78B | ― | -31.26% | ― | 104.04% | 87.80% | |
49 Neutral | $6.84B | 0.05 | -53.14% | 2.48% | 24.49% | -3.26% | |
48 Neutral | $11.58M | ― | -184.09% | ― | ― | 68.50% | |
41 Neutral | $63.37M | ― | 41.08% | ― | -0.55% | 49.85% |
* Healthcare Sector Average
Performance Comparison
BLRX
Bioline RX Ltd Sponsored ADR
3.05
-42.95
-93.37%
EXEL
Exelixis
36.80
13.82
60.14%
KPTI
Karyopharm Therapeutics
6.94
-15.71
-69.36%
BPMC
Blueprint Medicines
89.84
-0.66
-0.73%
Bioline RX Ltd Sponsored ADR Earnings Call Summary
Earnings Call Date: Nov 25, 2024 | % Change Since: -72.57% | Next Earnings Date: Mar 26, 2025
Earnings Call Sentiment Positive
The earnings call highlighted a major licensing agreement and debt restructuring, which position BioLineRx favorably for future growth and stability. However, challenges remain, including a net loss, closure of U.S. operations, and uncertainty around China market revenues.Highlights
Significant Licensing Agreement with Ayrmid Limited
BioLineRx executed an exclusive license agreement with Ayrmid Limited for motixafortide, securing a $10 million upfront payment, $87 million in potential commercial milestones, and royalties between 18% and 23%.
Equity Investment and Debt Restructuring
BioLineRx received a $9 million equity investment from Highbridge Capital, which along with the licensing agreement, enabled repayment of $16.5 million of debt and restructuring of remaining debt under favorable terms with BlackRock.
APHEXDA Market Penetration
APHEXDA achieved formulary placement at institutions managing over 40% of transplant procedures and reached a 10% market share of total CXCR4 inhibitor usage in the U.S.
Strong Financial Performance
Reported $4.9 million in total revenue for Q3 2024, marking an increase from no recorded revenue in Q3 2023.
Cost Reduction and Cash Runway
BioLineRx's annual cash burn is expected to reduce by over 70% starting January 1, 2025, with a cash runway extending into 2026.
Lowlights
Net Loss Despite Revenue Growth
Reported a net loss of $5.8 million for Q3 2024, though it was a reduction from a $16 million net loss in Q3 2023.
Closure of U.S. Commercial Operations
BioLineRx is shutting down its U.S. commercial operations following the licensing agreement with Ayrmid.
Uncertainty in China Market Revenue
Revenue from China market through Gloria Biosciences is uncertain and not expected until possibly 2025.
Company Guidance
During the BioLineRx third quarter 2024 financial results conference call, the company provided guidance on several key metrics. The recent license agreement with Ayrmid Limited for motixafortide, branded as APHEXDA, included a $10 million upfront payment, potential commercial milestones of up to $87 million, and royalties ranging from 18% to 23%. Additionally, a $9 million equity investment from Highbridge Capital was received. The company plans to cut its annual cash burn by over 70% starting January 1, 2025, with a cash runway extending into 2026. BioLineRx achieved a 10% market share in the U.S. CXCR4 inhibitor market by the end of Q3 2024, with APHEXDA being placed on formularies covering over 40% of transplant procedures. They also reported a net revenue of $1.7 million from APHEXDA product sales in the U.S. for the quarter.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.